	I.1. Consignor				I.2. IMSOC reference	I.2.a. Local refere	nce		
	Name					I.3. Central Competent Authority			
	Address						-		
	Country		ISO Code			I.4. Local Compete	ent Authority		
t	I.5. Consignee				I.6. Operator conducting assembly operations independently of an establishment				
nei	Name				Name				
E	Address		ICO Cada		Address				
<u>isi</u>	Country		ISO Code		Approval Number				
5					Country	ISO Code			
J	I.7. Country of orig	v in		ISO Code	I.9. Country of destination	ISO Code			
B	in councy of one								
Part I: Description of consignment	I.8. Region of origi	n		Code	I.10. Region of destination		Code		
SCL	I.11. Place of dispa	itch			I.12. Place of destination				
De	Name				Name				
н	Address				Address				
Ш	Country	Approval Number Country ISO Code			Approval Number	ISO Code			
РЧ	-		100 0000		Country ISO Code				
	I.13. Place of loadi	ng			I.14. Date and time of departure				
	Name								
	Address								
	Approval Number Country	ſ	ISO Code						
	-								
	I.15. Means of Tra		I donatifi o ati o a		I.16. Transporter				
	Mode	International transport	Identification		Name				
		document			Address Activity ID				
					Country	ISO Code			
					I.17. Accompanying documents				
					Accompanying document reference				
					Date of issue				
					Country Place of issue				
	I.18. Transport coi	nditions							
	Ambient 🗆		Chille	ed 🗆	Frozen 🗆				
	140. C	(0)N.							
	I.19. Container No	/ Seal No							
	I.20. Certified as		Quarantine or sin	nilar	Organic fertilizers and soil		_		
	Travelling circus/a	animal act 🗀	establishment \Box	inar	improvers	Confined establis	hment 🗀		
	Slaughter 🛛		Dispatch centre [Further processing \Box	Registered equida	ie 🗆		
	Germinal product	s 🗆	Exhibition \Box		Event or activity near borders \Box	Release into the w	rild 🗆		
	Products for huma	an consumption	Further keeping		Ornamental aquaculture	Other 🗆			
					establishment \Box				
	Relaying 🗆		Live aquatic anim consumption	als for human	Technical use 🗆				
	I.21. For transit through a third country								
	Third country				ISO Code				
	Exit point				BCP code				
	Entry point		+-(-) —		BCP code				
		rough Member Sta			I.23. For export				
	Member State		ISO Code		Third country	ISO Code			
	I.24. Estimated jou	Irnev time			Exit point I.25. Journey Log	BCP code			
		-							
	I.27. Total quantity				I.28. Total gross weight				
	I.30. Description o	-							
	1. 01 LIVE ANIMA	LS							
	0103 Live swine	9							

UROPEAN UNION								
	#1.	Commodity	Subcategory	Sex	Identification system			
	Species	S	Identification Number	Age	Quantity			

_	KOI LAN					establistilleri						
	II. Health info	ormation										
	I, the unde	rsigned offi	cial veterin	arian, hereb	by certify, tha	t:						
	II.1.	.The anima	nals(1) in the consignment described in Part I meet the following requirements:									
		II.1.1.		Their confined establishment of dispatch is approved in accordance with Articles 97 and 99 of Regulation (EU) 2016/429.								
r al l II. Cel ull'autol		II.1.2.	listed in An examination	nnex of Com on, or wher 48 hour per	nmission Imp e this is not p	s or symptoms of diseases, in particular relevant diseases plementing Regulation (EU) 2018/1882, during the clinical possible, a clinical inspection, which was carried out departure of the consignment, on (insert						
מדרידי	II.2.	-	to official in uirements:	o official information, animals in the consignment described in Part I meet the following rements:								
ÿ		II.2.1.	-		fined establis to be moved.	shment that is not subject to	movement restrictions					
	(2)(3) 🗆 either	[II.2.2.	(serotypes	1-24), wher	e no case of i	•	rus (serotypes 1-24) has beer					
			vaccinated 60 day per	l with a live riod before t	vaccine agai he date of mo	ns in the targeted animal pop nst infection with bluetongu ovement and the requirement Commission Delegated Reg	e virus (serotypes 1-24) in th nts laid down in Article					
	(2)(3) □ [II.2.2. They originate from a Member Sta and/or infection with bluetongue virus (se 32(1)(a), (b) or (c) or Article 32(2) o they					rotypes 1-24) and the requir	ements laid down in Article					
	(2) 🗆 either [II.2.2.1. have been kept in a Me						ly free from infection with h Article 40(3) of Commissio					
		(2)	🗆 either	[II.2.2.1.1.	for at least (50 days prior to the date of n	novement]]					
		(2)	□ and/or		for at least 2 subjected to samples col animal into	28 days prior to the date of n a serological test, with nega lected at least 28 days follow	novement and have been ative results, carried out on ring the entry date of the easonally free from infectior					
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at the Member	•	sults, carried out on samples entry date of the animal into					
	(2)	□ and/or	[II.2.2.2.	place of de			during transportation to the gainst attacks by vectors in a					
		(2)	🗆 either	[II.2.2.2.1.	for at least (60 days prior to the date of n	novement]] .					
		(2)	□ and/or	[II.2.2.2.2.	subjected to samples col	28 days prior to the date of n a serological test, with nega lected at least 28 days follow nent of the period of protect	tive results, carried out on ring the date of the					
		(2)	□ and/or	[II.2.2.2.3.	subjected to collected at	•	sults, carried out on samples late of the commencement o					
	(2)	□ and/or	[II.2.2.3.			gainst those serotypes from were reported during the p						

	II. Health info	ormation								
				State or zo	ne and are w	vithin the im	munity period g	uaranteed in the		
				specification	ons of the va	ccine and				
		(2)	🗆 either	[II.2.2.3.1.	have been v movement]		ore than 60 days	s before the date of	-	
Part II: Certification		(2)	□ and/or	[II.2.2.3.2.	PCR test, wi	ith negative i	results on sample	d vaccine and subj es collected at least e specifications of t	14 days	
rt II: Ceri	(2)	□ and/or	[II.2.2.4.	specific an	itibodies agai	inst all seroty		gical test able to de ction with bluetong te or zone and		
Pai		(2)	□ either	[II.2.2.4.1.	. the serological test has been carried out on samples collected at least 60 days before the date of movement]]					
		(2)	□ and/or	[II.2.2.4.2.	2. the serological test has been carried out on samples collected at least 30 days before the date of the movement and the animal has been subjected to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of movement;]]]					
	(2)(3) 🗆 and/or	[II.2.2.	virus (sero bluetongu	otypes 1-24) e virus (serc	the from a Member State or a zone neither free from infection with bluetongue (pes 1-24) nor covered by the eradication programme for infection with virus (serotypes 1-24) and the requirements laid down in Article 32(1)(a), (b) or 232(2) of Delegated Regulation (EU) 2020/688 are fulfilled, and they					
	(2)	□ either	[II.2.2.1.	place of de		d have been	kept protected a	luring transportati gainst attacks by ve		
		(2)	🗆 either	[II.2.2.1.1.	for at least	60 days prio	r to the date of m	novement]]		
		(2)	□ and/or	[II.2.2.1.2.	subjected to samples col	o a serologica llected at lea	al test, with nega st 28 days follow	novement and have tive results, carried ing the date of the ion against attacks	d out on	
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at	o a PCR test, least 14 day	with negative re	novement and have sults, carried out or ate of the commen by vectors;]]]	n samples	
	(2)	□ and/or	[II.2.2.2.	have been kept at least for the 60 day period prior to departure in an establishment situated in a Member State or in an area of at least 150 km radius centred on the establishment, where surveillance in compliance with the requirements laid down in Sections 1 and 2 of Chapter 1 of Part II of Annex V to Delegated Regulation (EU) 2020/689 has been carried out during that period and					he nnex V to	
		(2)	□ either	[II.2.2.2.1.	24 of infect the past 2 y place where	ion with blue ears in an ar e the animal	etongue virus wh ea of at least 150 s were kept and	st those serotypes f nich were reported) km radius centred are within the imm of the vaccine and	during l on the	
			(2)	🗆 either	[II.2.2.2.1.1.	have been v of moveme		than 60 days befor	e the date	
			(2)	□ and/or	[II.2.2.2.1.2.	have been v subjected to collected at	vaccinated with a of a PCR test, with	an inactivated vacc negative results on er the onset of the ne vaccine;]]]]	n samples	
		(2)	□ and/or	[II.2.2.2.2.	24 of infect the past 2 y	ion with blue ears in an ar	etongue virus wł	ist those serotypes nich were reported) km radius centred	during	

II. Booth information (2) • either [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 50 days before the date of movement]] (2) • or [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected at lease 30 days before the date of the movement and the application of the analysis of the movement is and the subjected with positive results carried out on samples collected at lease 30 days before the date of movement and the date of movement and the set of origin authorised novement is antimals to another Member State of origin authorised novement is antimis to another Member State of control the Commission and the other Member State of action in factorial state state state. In the Member State of a control (EU) 2020(689 and the competent authority of the Member State of action is referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (c)) = either (2) either III.2.2.1. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Deleg	_	-	KOI LAN						<u> </u>		
Image: Second			II. Health info	ormation							
1000000000000000000000000000000000000					(2)	∘ either	[II.2.2.2.2.1.	a serological test carried out on samples collected at lea			
(2) □ either [II.2.2.1.] with the status free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State state state submitted subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ either [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and (2) □ and/or [II.2.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State stat such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to	ertification	eruncation			(2)	0 or	[II.2.2.2.2.2.	a serological test carried out on samples collected at lea 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of			
the Member State of destination has informed the commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020(688 and the requirements Laid down in Article 33 of that Delegated Regulation are fulfilled.]]] (2) and/or [II.2.2.2.4) with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of Astat Such Novement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (2) either [II.2.2.2.2] point 5 of Section		Part II: C		[II.2.2.	Part II of A State of or	Annex V to Regulation (EU) 2020/689 and the competent authority of the Membe					
L Delegated Regulation, and (2) and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States that such movement is authorised subject to the conditions referred to in Article 32(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(688 and (2) either [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and			(2)	□ either	[II.2.2.1.	the Memb Member S referred to	er State of de tates that suc	estination has informed the Commission and the other ch movement is authorised subject to the conditions	1		
(2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.3.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [(2)	□ either	[II.2.2.1.1.					
Part of the second s				(2)	□ and/or	[II.2.2.1.2.	-	-			
Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation are fulfilled;]]] (2) and/or </td <th></th> <td></td> <td></td> <td>(2)</td> <td>□ and/or</td> <td>[II.2.2.1.3.</td> <td></td> <td></td> <td></td>				(2)	□ and/or	[II.2.2.1.3.					
32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the o				(2)	□ and/or	[II.2.2.1.4.	-	-			
 (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ either [II.2.2.2.1] point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.2] point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.3] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) □ and/or [II.2.2.3] neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member Sta							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements			
Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.3.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3.1. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member (2) either [II.2.2.3.1. without any conditions, and (2) <td< td=""><th></th><td></td><td>(2)</td><td>□ and/or</td><td>[II.2.2.2.</td><td>(serotypes Commission subject to</td><td>1-24) and the ot the condition</td><td>e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated</td><td></td></td<>			(2)	□ and/or	[II.2.2.2.	(serotypes Commission subject to	1-24) and the ot the condition	e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated			
Cancel and/or [II.2.2.3.] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and Cancel C				(2)	□ either	[II.2.2.2.1.					
 (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	\Box and/or	[II.2.2.2.2.					
 Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	\Box and/or	[II.2.2.2.3.					
 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	□ and/or	[II.2.2.2.4.	-	-			
 by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) □ either [II.2.2.3.1. without any conditions, and (2) □ and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements			
(2)			(2)	□ and/or	[II.2.2.3.	by the erac 24) and the	dication prog e Member St	gramme for infection with bluetongue virus (serotypes 1 ate of destination has informed the Commission and the	l-		
(2)				(2)	🗆 either	[II.2.2.3.1.	without any	y conditions, and			
							subject to th	he conditions referred to in point 5 of Section 1 of Chapt	er		
				(2)	□ and/or	[II.2.2.3.3.			er		

	II. Health info	rmation						
	n. nearth hno	Titlation						
	2 of Part II of Annex V to Delegated						egu	lation (EU) 2020/689, and
		(2)	□ and/or	[II.2.2.3.4.		e conditions referred to in of Annex V to Delegated Re	-	oint 7 of Section 1 of Chapter lation (EU) 2020/689, and
		(2)	□ and/or	[II.2.2.3.5.		e conditions referred to in of Annex V to Delegated Re		oint 8 of Section 1 of Chapter lation (EU) 2020/689, and
Part II: Certification					32(2) of Dele	nents laid down in Article egated Regulation (EU) 202 n Article 33 of that Delegat	20/6	
<mark>.</mark>	II.3	To the bes	t of my know	wledge and a	as declared b	y the operator:		
Part II		II.3.1.				spatch there are no abnor nimals to be moved.	ma	l mortalities with an
		II.3.2.				nct with animals which are .1., or with animals of a low		-
		II.3.3.	not pose a		risk at the co	nce plan of the confined e nfined establishment of de		ablishment, the animals do nation for the spread of
	II.4.	-	ents are ma 1 (EU) 2020/6	-	ort the consig	gnment in accordance witl	h A	rticle 4 of Delegated
	II.5.	animals, tł		10 days for				ansport by waterway/sea of nded by the duration of the
	lumpy skir		compliance			n relation to emergency pr d Annex IX, Part 3, point (3		ective vaccination against), to Commission Delegated
	skin diseas		iance with A			lation to emergency protec x IX, Part 3, point (3.2), to (ve vaccination against lumpy nmission Delegated
	Animal we	lfare attesta	ation					
		ovisions of				h certificate were fit to be n the intended journey due		
	Notes:							
	In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Union in this certificate include the United Kingdom in respect of Northern Ireland.							lar Article 5(4) of the
	This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.							ion of certificates provided
	Part I:							
	Box reference I.11:		lispatch": In ion (EU) 201		fined establis	shment approved in accore	dar	nce with Articles 97 and 99
	Box "Place of destination": Indicate a confined establishment approved in accordance with Articles 97 and reference 99 of Regulation (EU) 2016/429. I.12:						dance with Articles 97 and	
	Part II:							
	(1)	There can	be one or m	nore animals	s in the consig	gnment.		
	(2)	Delete if n	ot applicabl	e.				

	II. Health info	rmation		
	(3)	Only in case of animals belonging to the family Giraffidae, Moschidae or Tragulidae.	ies Antilocapridae, Bovidae, C	amelidae, Cervidae,
	Certifying Off	icer/Official veterinarian		
	Name (in capi	tal letters)	Qualification and title	
n	Date of signat Stamp	ure	Signature	
Part II: Certification	Stamp			
ũса				
rtif				
Ce				
t II:				
art				
Н				